Contrast Media: Safety Issues and ESUR Guidelines

Description

Front Matter....Pages I-XIII Classification and Terminology....Pages 3-9 Requests for Imaging Using Contrast Agents: What Information Must be Provided....Pages 11-14 Off-Label Use of Medicines: Legal Aspects....Pages 15-19 Pharmacovigilance: When to Report Adverse Reactions....Pages 21-23 What is Required in Order to Get the Authorities to Approve a New Contrast Agent–....Pages 25-29 A Critical Review of Meta-Analysis of Adverse Events After Contrast Agents....Pages 31-39 Prevention of Acute Reactions....Pages 43-51 Management of Acute Adverse Reactions....Pages 53-60 Contrast Medium-Induced Nephropathy....Pages 63-80 Dialysis and Contrast Media....Pages 81-85 Non-Insulin-Dependent Diabetes and Contrast Media....Pages 87-92 Pregnancy and Lactation....Pages 95-101 Phaeochromocytoma....Pages 103-105 Interactions with Other Drugs and Clinical Tests....Pages 107-113 Extravasation Injury....Pages 115-119 Late Adverse Reactions....Pages 123-127 Effects on the Blood and Endothelium....Pages 129-138 Effect on Thyroid Function....Pages 139-146 Pulmonary Effects....Pages 147-152 Chelates and Stability....Pages 155-160 Safety of Ultrasonographic Agents....Pages 215-219 Barium Preparations: Safety Issues....Pages 223-226 Diagnostic Efficacy....Pages 161-169 Radiography with Gadolinium Contrast Agents....Pages 171-177 ESUR Guidelines on Contrast Media....Pages 229-242 Official Publications from the European Society of Urogenital Radiology....Pages 243-243 Acute Adverse Reactions....Pages 181-185 Delayed Reactions: Nephrogenic Systemic Fibrosis....Pages 187-196 Gadolinium-Based Contrast Agents....Pages 199-204 Non-Gadolinium-Based Contrast Agents....Pages 205-212 Back Matter....Pages 245-254